GRI BIO, Inc. financial data

Symbol
GRI on Nasdaq
Industry
Pharmaceutical Preparations
Location
2223 Avenida De La Playa, Suite 208, La Jolla, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Vallon Pharmaceuticals, Inc. (to 4/21/2023)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 236 %
Debt-to-equity 75.2 % -86.5%
Return On Equity -289 % +92.3%
Return On Assets -165 % +61.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.93M shares +175%
Common Stock, Shares, Outstanding 5.02M shares +69.9%
Entity Public Float 9.5M USD +82.7%
Weighted Average Number of Shares Outstanding, Basic 3.16M shares +9630%
Weighted Average Number of Shares Outstanding, Diluted 3.16M shares +9630%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD
Research and Development Expense 3.99M USD +286%
General and Administrative Expense 4.32M USD -42.8%
Operating Income (Loss) -8.31M USD +3.29%
Net Income (Loss) Attributable to Parent -8.26M USD +37.9%
Earnings Per Share, Basic 286 USD/shares +99%
Earnings Per Share, Diluted 286 USD/shares +99%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.75M USD +36.1%
Cash, Cash Equivalents, and Short-term Investments 1.67M USD -67.8%
Assets, Current 5.32M USD +21.9%
Property, Plant and Equipment, Net 5K USD -44.4%
Operating Lease, Right-of-Use Asset 131K USD +368%
Other Assets, Noncurrent 0 USD -100%
Assets 5.46M USD +24%
Accounts Payable, Current 1.14M USD +15.1%
Employee-related Liabilities, Current 282K USD -68%
Accrued Liabilities, Current 531K USD -53.5%
Liabilities, Current 1.72M USD -21.2%
Operating Lease, Liability, Noncurrent 84K USD
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 1.8M USD -17.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -37.8M USD -28%
Stockholders' Equity Attributable to Parent 3.66M USD +64.3%
Liabilities and Equity 5.46M USD +24%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.2M USD -280%
Net Cash Provided by (Used in) Financing Activities 4.49M USD +336%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 5.02M shares +69.9%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.28M USD +406%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.75M USD +36.1%
Deferred Tax Assets, Valuation Allowance 14.5M USD +315%
Deferred Tax Assets, Gross 14.5M USD +313%
Operating Lease, Liability 14K USD -80.3%
Depreciation 1K USD 0%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -6.78M USD +27.2%
Lessee, Operating Lease, Liability, to be Paid 14K USD
Property, Plant and Equipment, Gross 34K USD 0%
Operating Lease, Liability, Current 47K USD +67.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 14K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 12.8M USD +300%
Share-based Payment Arrangement, Expense 147K USD -25%